Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026850 (
muscular dystrophy
)
5,870
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The immune response to dystrophin-deficient muscle promotes the pathology of Duchenne muscular dystrophy (DMD) and the mdx mouse model of DMD. In this investigation, we find that the release of major basic protein (MBP) by eosinophils is a prominent feature of DMD and mdx dystrophy and that eosinophils lyse muscle cells in vitro by the release of
MBP-1
. We also show that eosinophil depletions of mdx mice by injections of anti-chemokine receptor-3 reduce muscle cell lysis, although lysis of mdx muscle membranes is not reduced by null mutation of
MBP-1
in vivo. However, ablation of
MBP-1
expression in mdx mice produces other effects on
muscular dystrophy
. First, fibrosis of muscle and hearts, a major cause of mortality in DMD, is greatly reduced by null mutation of
MBP-1
in mdx mice. Furthermore, either ablation of
MBP-1
or eosinophil depletion causes large increases in cytotoxic T-lymphocytes (CTLs) in mdx muscles. The increase in CTLs in
MBP-1
-null mice does not reflect a general shift toward a Th1 inflammatory response, because the mutation had no significant effect on the expression of interferon-gamma, inducible nitric oxide synthase or tumor necrosis factor. Rather,
MBP-1
reduces the activation and proliferation of splenocytes in vitro, indicating that
MBP-1
acts in a more specific immunomodulatory role to affect the inflammatory response in
muscular dystrophy
. Together, these findings show that eosinophil-derived
MBP-1
plays a significant role in regulating
muscular dystrophy
by attenuating the cellular immune response and promoting tissue fibrosis that can eventually contribute to increased mortality.
...
PMID:Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. 1843 Jul 16